

NON-INTERVENTIONAL STATISTICAL ANALYSIS PLAN FOR SECONDARY DATA COLLECTION STUDY

VERSION HISTORY

Version	Effective Date	Change Type (New, Revise, Admin)	Summary of Revisions
1.0	01-24-2022		

PFIZER CONFIDENTIAL CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 1 of 33



Non-Interventional Study Protocol B1791096

A Real-World Study Evaluating the Safety of Pantoprazole Sodium IV in Infants Aged 1 Month to <1 Year and Patients Aged 1 to <2 Years Using an Electronic Health Records Database from the United States

Statistical Analysis Plan (SAP)

Version: 1.0

Author:

Taylor, Benjamin Vice president, Science Aetion, Inc.

Date: 01-24-2022

TABLE OF CONTENTS

LIST OF TABLES	5
LIST OF FIGURES	5
1. AMENDMENTS FROM PREVIOUS VERSION(S)	6
2. INTRODUCTION	6
2.1. STUDY DESIGN	6
2.1.1. Study population	7
2.1.2. Data source	8
2.1.3. Treatment/cohort labels	9
2.2. STUDY OBJECTIVES	9
3. HYPOTHESES AND DECISION RULES	0
3.1. STATISTICAL HYPOTHESES	0
3.2. STATISTICAL DECISION RULES	0
4. ANALYSIS SETS/POPULATIONS	0
4.1. FULL ANALYSIS SET (FAS)1	1
4.1.1. Exclusion criteria1	2
4.2. SAFETY ANALYSIS SET	2
4.3. OTHER ANALYSIS SET1	2
4.4. SUBGROUPS	2
5. ENDPOINTS AND COVARIATES	4
5.1. EFFICACY/EFFECTIVENESS ENDPOINT(S)14	4
5.2. SAFETY ENDPOINTS14	4
5.3. OTHER ENDPOINTS	1
5.4. KEY VARIABLES OF INTEREST2	1
5.4.1. Demographic characteristics	1
5.4.2. Comorbidities	2
5.4.3. Duration and dose of IV Pantoprazole	6
6. HANDLING OF MISSING VALUES	6
7. STATISTICAL METHODOLOGY AND STATISTICAL ANALYSES	6
7.1. STATISTICAL METHODS	6
7.2. STATISTICAL ANALYSES	8

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 3 of 33

7.2.1. Safety Analyses	28
7.2.2. Sensitivity Analyses	28
7.2.3. Summary of Analyses	29
8. LIST OF TABLES AND TABLE SHELLS	31
9. REFERENCES	32
10. APPENDICES	33
10.1. APPENDIX 1: DATA DERIVATION DETAILS	33
10.1.1. Definition and use of visit windows in reporting	33
10.1.2. Further definition of endpoints	33
10.2. APPENDIX 2: ADDITIONAL STATISTICAL METHODOLOGY DETAILS	33
10.2.1. Further Details of the Statistical Methods	33
10.3. APPENDIX 3: DIAGNOSIS AND PROCEDURE CODES USED IN THE STUDY	33

LIST OF TABLES

Table 1.	NDC and HCPCS Codes Indicating IV Dispensing of pantoprazole	.10
Table 2.	Operationalization of subgroups	.13
Table 3.	Outcomes of Interest	.14
Table 4.	Operationalization of Comorbidities	22
Table 5.	Sensitivity Analyses	28
Table 6.	Summary of Analyses	29
Table 7.	List of Table Shells	.31

LIST OF FIGURES

Figure 1.	Flow Diagram of Patient Selection for Cohort 1*	1
Figure 2.	Flow Diagram of Key Study Time Points	}

1. AMENDMENTS FROM PREVIOUS VERSION(S)

N/A

2. INTRODUCTION

Protonix® (pantoprazole sodium) IV for Injection is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE) [PROTONIX® I.V. (pantoprazole sodium) for injection, for intravenous use USPI]. It is also indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome in adults. Protonix IV is currently not indicated for use in pediatric patients.

The Food and Drug Administration (FDA) issued a requirement for a deferred study under the Pediatric Research Equity Act (PREA) for the treatment of GERD in patients 0 to 16 years of age as a Post Marketing Requirement (PMR) number 145-1 in December 2004 (06 December 2004 letter to NDA 20-988/S-027). Currently, there is an ongoing clinical trial B1791089 conducted in patients 1 to 16 years of age. However, infants aged 1 month to <1 year cannot be enrolled into the ongoing clinical trial. Also, there may be insufficient number of patients aged 1 to <2 years enrolled in the ongoing trial. For these reasons, patients in both these two age-groups are being pursued to be included in this non-interventional study.

This non-interventional study is designated as a Post-Authorization Safety Study (PASS) and is proposed voluntarily by Pfizer to collect safety data in two separate cohorts of infants aged 1 month to <1 year and patients aged 1 to <2 years who were treated with IV pantoprazole, with a primary focus on patients with a diagnosis of GERD with or without EE using an electronic health records database from the United States. In addition to this study, pharmacokinetic (PK) modeling and simulation is being pursued in lieu of an interventional clinical study as another strategy to address this post marketing requirement.

2.1. STUDY DESIGN

This will be a retrospective cohort study without a comparator group. No a priori hypotheses are specified. Descriptive analyses, including an estimation of incidence rates, will be performed. This study will estimate the incidence of a number of outcomes of interest following the intravenous administration of pantoprazole sodium in infants for the treatment of GERD, with or without EE. Patients will enter the cohort on the date of first administration of pantoprazole sodium IV defined as the index date and will be followed for the occurrence of whichever of the following occurs first: any outcome of interest 90 days following the discontinuation of the first IV pantoprazole episode (a gap of <7 days between administrations will be considered one episode), initiation of a separate IV pantoprazole infusion within 90 days following the discontinuation of the discontinuation of the first IV pantoprazole dispensing,

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020


Page 6 of 33

where a separate infusion is defined as the subsequent dispensing at least 7 days from the end of the previous infusion, death, end of enrollment in the database, end of study period (ie, December 31, 2020).

2.1.1. Study population

Two separate cohorts of patients, ie, infants aged 1 month to <1 year and patients aged 1 to <2 years will be identified. The study period will be defined from January 1, 2007 to December 31 2020.

Figure 1. Flow Diagram of Patient Selection for Cohort 1*



* Footnotes:

1. Cohort 2 will have the same patient selection process, but will be for patients aged 1 to <2 years.

2. During the analysis phase, patients with a specific outcome of interest prior to the index date will be excluded from the incidence rate calculation of that outcome. These patients will be included in the incidence rate calculation of all other outcomes.

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 7 of 33

090177e19a9b0eb9\Approved\Approved On: 30-Jun-2022 03:30 (GMT)




Figure 2. Flow Diagram of Key Study Time Points

2.1.2. Data source

The study will be conducted using Optum's longitudinal integrated EHR from the US.¹ This data source includes data from adjudicated administrative insurance claims, inpatient electronic health records, as well as outpatient EHR enabling capture of exposure to IV pantoprazole in the study population of interest.

The Optum EHR with Integrated Claims dataset from the US contains electronic health records data with prescriptions, diagnoses, and provider information as well as practice management data and claims information for deterministically matched patients. The population of the dataset is made up of commercial health plan members and Medicare Advantage members, across all 50 states. The database currently encompasses the claims and EHR data of more than 95 million patients with approximately 1.9 million patients aged less than 2 years from January 1, 2007 through Dec 31, 2020. This dataset contains a combination of structured data (e.g. diagnoses, procedures, prescriptions) and information from unstructured data (e.g. drug rationale, provider notes) from the electronic health record and corresponding claims information for those instances. The claims are verified, adjudicated, and adjusted by the relevant insurer, and de-identified by Optum prior to providing access to the database. Patients are only included in the database if they had both medical and prescription drug coverage, as well as the EHR information. Information is processed, normalized, and standardized across the continuum of care from both acute inpatient stays and outpatient visits. Optum® data elements include demographics, medications prescribed and administered, immunizations, allergies, lab results (including microbiology), vital signs and other observable measurements, clinical and inpatient stay administrative data and coded diagnoses and procedures.

PFIZER CONFIDENTIAL CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 8 of 33

2.1.3. Treatment/cohort labels

Cohort 1: Infants aged 1 month to <1 year, who were treated with IV pantoprazole

Cohort 2: Patients aged 1 to <2 years, who were treated with IV pantoprazole

2.2. STUDY OBJECTIVES

<u>Primary Objective</u>: To estimate the incidence of the following outcomes of interest in infants aged 1 month to <1 year and patients aged 1 to <2 years with a diagnosis of GERD with or without EE and treated with IV pantoprazole:

- Agranulocytosis
- Thrombocytopenia
- Leukopenia
- Pancytopenia
- *Hypersensitivity (including anaphylactic reactions and anaphylactic shock)*
- Hyperlipidaemia
- Hypertrigliceridema
- Hyponatraemia
- Hypomagnesaemia
- Hypocalcaemia
- Hypokalaemia
- Diarrhea
- Vomiting
- Abdominal distension
- *Hepatobiliary injury*
- Urticaria
- Angioedema
- Stevens-Johnson syndrome
- Lyell syndrome
- Erythema multiforme
- Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)
- Tubulointerstitial nephritis
- Photosensitivity
- Peripheral edema
- Injection site thrombophlebitis

<u>Secondary Objective 1</u>: To estimate the incidence of the above-mentioned outcomes of interest in infants aged 1 month to <1 year and patients aged 1 to <2 years treated with IV pantoprazole without a diagnosis of GERD or EE.

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 9 of 33 <u>Secondary Objective 2:</u> To provide the frequency of the 25 most common diagnostic codes occurring within 30 days prior to the start of IV pantoprazole (ie, index date) through 90 days of last treatment with IV pantoprazole among infants aged 1 month to <1 year and patients aged 1 to <2 years with a diagnosis of GERD (regardless of EE diagnosis).

3. HYPOTHESES AND DECISION RULES

3.1. STATISTICAL HYPOTHESES

N/A

3.2. STATISTICAL DECISION RULES

N/A

4. ANALYSIS SETS/POPULATIONS

Two separate cohorts of patients, ie, infants aged 1 month to <1 year and patients aged 1 to <2 years will be identified. Patients will enter the study on their index date, given that they meet all inclusion criteria and exclusion criterion described in <u>Section 4.1</u>.

Exposure to IV pantoprazole will be identified from inpatient procedure and drug codes including any of the following National Drug Codes (NDC) and Healthcare Common Procedure Coding System (HCPCS) codes shown in Table 1. Only the first treatment episode during the study period will be of interest. Any subsequent infusion occurring within 7 days after the end of the previous infusion will be considered one treatment episode.

Code	Description	
NDC		
0008-0941-01	40 mg/vial pantoprazole	
0008-0941-02	40 mg/vial pantoprazole (10 vials)	
0008-0941-03	40 mg/vial pantoprazole (25 vials)	
0008-2001-01	40 mg/vial pantoprazole Single vial	
0008-2001-10	40 mg/vial pantoprazole 10 vials	
0008-2001-25	40 mg/vial pantoprazole 25 vials	
	PFIZER CONFIDENTIAL	

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020

Page 10 of 33

Code	Description	
0008-4001-01	40mg/vial pantoprazole Single vial	
0008-4001-10	40 mg/vial pantoprazole 10 vials	
0008-4001-25	40 mg/vial pantoprazole 25 vials	
0008-0923-51	40 mg/vial pantoprazole Single vial	
0008-0923-55	40 mg/vial pantoprazole 10 vials	
0008-0923-60	40 mg/vial pantoprazole (25 vials)	
HCPCS	<u> </u>	
S0164Injection pantoprazole sodium, 40 mg		
<i>C</i> 9113	Injection, pantoprazole sodium, per vial	

 Table 1.
 NDC and HCPCS Codes Indicating IV Dispensing of pantoprazole

4.1. FULL ANALYSIS SET (FAS)

Two separate cohorts of patients, ie, infants aged 1 month to <1 year and patients aged 1 to <2 years will be identified. Patients will enter the study on their index date, given that they meet all inclusion criteria and exclusion criterion below:

Inclusion Criteria

- 1. At least one administration of IV pantoprazole during the study period from January 1, 2007 to December 31, 2020, and
- 2. For the cohort of infants aged 1 month to <1 year (Cohort 1): Age 1 month to < 1 year on the index date (ie, the date of first prescription or administration of IV pantoprazole); For the cohort of patients aged 1 to <2 years (Cohort 2): Age 1 to <2 years on the index date.
- 3. Patients must be enrolled in the database for at least 30 days prior to the index date

In addition to the minimum of 30-days of baseline enrollment, patients will be further excluded based on the occurrence of a history of outcomes of interest identified in <u>Section 5.2</u> occurring prior to the index date.

PFIZER CONFIDENTIAL CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 11 of 33

4.1.1. Exclusion criteria

1. Patients with any of the following ICD-9-CM or ICD-10-CM codes occurring prior to or on the index date indicating a preterm birth or birth weight less than 2.36 kilograms will be excluded:

ICD-9-CM codes: 765.01-765.08; 765.10-765.19; 765.21-765.28

ICD-10-CM codes: P07.21-P07.26; P030-P039; P07.01-P07.03; P07.14-P07.18

The cut-off of birth weight less than 2.36 kilograms is defined based on a birth weight that is less than 3rd percentile weight for males at birth obtained from Centers for Disease Control and Prevention (CDC) infant weight-for-age charts (available at URL: https://www.cdc.gov/growthcharts/html_charts/wtageinf.htm). It is reasonable to assume that infants with birth weight less than 2.36 kilograms are most likely born preterm.

4.2. SAFETY ANALYSIS SET

The safety analysis set is the same as the full analysis set.

4.3. OTHER ANALYSIS SET

No additional analysis sets.

4.4. SUBGROUPS

Within each cohort (ie, Cohort 1 and 2), 3 subgroups will be identified as follows and as shown in Figure 1:

(1) Patients who have a diagnosis of GERD with EE: defined based on the presence of at least one of the ICD-9-CM or ICD-10-CM codes as shown in Table 2 and the presence of an additional ICD-9-CM or ICD-10-CM code for ulcer of the esophagus during the baseline period or on the index date, as shown in Table 2.

(2) Patients who have a diagnosis of GERD without EE: defined based on the presence of at least one of the ICD-9-CM or ICD-10-CM codes and no ICD-9-CM or ICD-10-CM code for ulcer of esophagus during the baseline period or on the index date, as shown in Table 2.

(3) Patients without a diagnosis of GERD or EE: defined as patients who do not have any of the ICD-9-CM or ICD-10-CM codes as shown in Table 2 during the baseline period or on the index date.

ICD-9-CM codes will be used to identify the subgroups prior to October 2015, after which ICD-10-CM codes will be used. No validated algorithm for GERD with or without EE were

PFIZER CONFIDENTIAL CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 12 of 33

090177e19a9b0eb9\Approved\Approved On: 30-Jun-2022 03:30 (GMT)

found to be available via literature review, therefore, a combination of clinical input, and the available codes identified in the literature will be used.² Additionally, there is no explicit ICD-9-CM code for GERD with/without esophagitis. Therefore, based on a cross-sectional study that examined the validity of diagnosis codes of benign upper gastrointestinal disorders using electronic patient records², and an online conversion tool maintained by the Center for Medicare Services and the Centers for Disease Control and Prevention (available at URL: https://icd.codes/convert/icd10-to-icd9-cm), the subgroups of GERD with or without EE will be determined using the operational definitions shown in Table 2:

Subgroup	ICD-10- CM Code	Description of ICD- 10-CM code	ICD-9- CM Code	Description of ICD-9- CM code
<i>GERD</i> without <i>EE</i> [*]	K21.0	GERD with esophagitis	530.10, 530.11, 530.12, 530.19	Esophagitis unspecified Reflux esophagitis, Acute esophagitis, Other esophagitis
	K21.9	GERD without esophagitis	530.81	Esophageal reflux
GERD with EE	K21.0, K21.9	GERD with or without esophagitis	530.10, 530.11, 530.12, 530.19, 530.81	Esophagitis unspecified Reflux esophagitis, Acute esophagitis, Other esophagitis Esophageal reflux
			AND	
	K22.1	Ulcer of esophagus	530.2	Ulcer of esophagus

Table 2.	Operationalization of subgroups
----------	--

* Patients with any of the listed ICD-9-CM or ICD-10-CM codes and no ICD-9-CM code of 530.2 or ICD-10-CM code of K22.1 during the baseline period or on the index date will be included in the GERD without EE subgroup.

PFIZER CONFIDENTIAL CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 13 of 33

5. ENDPOINTS AND COVARIATES

The baseline period is defined as a period of minimum 30 days prior to index date (patients may have a baseline period greater than 30 days depending upon data availability prior to the index date). All comorbidities and exclusion criteria will be determined during this time period.

5.1. EFFICACY/EFFECTIVENESS ENDPOINT(S)

There will be no efficacy/effectiveness endpoints measured.

5.2. SAFETY ENDPOINTS

The first occurrence of each outcome is defined based on the presence of at least one ICD-9-CM or ICD-10-CM diagnosis code identified in an inpatient or outpatient setting during the follow-up period.

Outcome of interest	Operationalization: ICD-10- CM code	Operationalization: ICD-9-CM code		
Agranulocytosis	D70.2 Other drug-induced agranulocytosis D70.1 Agranulocytosis secondary to cancer chemotherapy	288.03 Drug induced neutropenia		
Thrombocytopeni a	D69.3 Immune thrombocytopenic purpura D69.59 Other secondary thrombocytopenia D69.6 Thrombocytopenia, unspecified D69.41 Evans syndrome D69.49 Other primary thrombocytopenia	287.31 Immune thrombocytopenic purpura 287.49 Other secondary thrombocytopenia 287.5 Thrombocytopenia, unspecified 287.32 Evans' syndrome 287.39 Other primary thrombocytopenia		

Table 3.Outcomes of Interest

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 14 of 33

Outcome of interest	Operationalization: ICD-10- CM code	<i>Operationalization: ICD-9-CM code</i> 288.51 Lymphocytopenia 288.59 Other decreased white blood cell count 288.50 Leukocytopenia, unspecified 288.09 Other neutropenia 288.00 Neutropenia, unspecified	
Leukopenia	D72.810 Lymphocytopenia D72.818 Other decreased white blood cell count D72.819 Decreased white blood cell count, unspecified D70.8 Other neutropenia D70.9 Neutropenia, unspecified		
Pancytopenia	D61.811 Other drug-induced pancytopenia D61.818 Other pancytopenia	284.12 Other drug-induced pancytopenia 284.19 Other pancytopenia	
Hypersensitivity (including anaphylactic reactions and anaphylacticK52.2x Allergic and dietetic gastroenteritis and colitis M31.0 Hypersensitivity angiitis T78.2x Anaphylactic shock, unspecified T78.4x Other and unspecified allergy M36.4 Arthropathy in hypersensitivity reactions classified elsewhere		558.3 Allergic gastroenteritis and colitis 446.20 Hypersensitivity angiitis, unspecified 446.21 Goodpasture's syndrome 446.29 Other specified hypersensitivity angiitis 995.0 Other anaphylactic reaction, NEC 995.3 Allergy, unspecified, NEC 713.6 Arthropathy associated with hypersensitivity reaction	
Hyperlipidemia E78.49 Other hyperlipidemia E78.5 Hyperlipidemia, unspecified		272.4 Other and unspecified hyperlipidemia	

Outcome of interest	Operationalization: ICD-10- CM code	Operationalization: ICD-9-CM code
Hypertrigliceride ma	E78.1 Pure hyperglyceridemia	272.1 Pure hyperglyceridemia
Hyponatremia	E87.1 Hypo-osmolality and hyponatremia	276.1 Hypo-osmolality and/or hyponatremia
Hypomagnesemia	E83.42 Hypomagnesemia	275.2 Disorders of magnesium metabolism
Hypocalcaemia	E83.51 Hypocalcemia	275.41 Hypocalcemia
Hypokalemia	E87.6 Hypokalemia	276.8 Hypopotassemia
Diarrhea	R19.7 Diarrhea, unspecified	787.91 Diarrhea
Vomiting	R11.10 unspecified R11.11 without nausea R11.12 Projectile vomiting R11.13 Vomiting of fecal matter R11.2 Nausea with vomiting, unspecified	536.2 Persistent vomiting 0 78.82 Epidemic vomiting syndrome 787.03 Vomiting alone 569.87 Vomiting of fecal matter 787.01 Nausea with vomiting
Abdominal distension	R14.0 Abdominal distension (gaseous)	787.3 Flatulence, eructation, and gas pain
Hepatobiliary injury	K71x Toxic liver disease K72x Hepatic failure, not elsewhere classified K72.00 Acute and subacute hepatic failure without coma K72.01 Acute and subacute hepatic failure with coma K72.10 Chronic hepatic failure without coma K72.11 Chronic hepatic failure with coma	 572.2 Hepatic encephalopathy. 572.8 Other sequelae of chronic liver disease 571.41 Chronic persistent hepatitis 571.49 Other chronic hepatitis 571.4 Chronic hepatitis 571.5 Cirrhosis of liver without mention of alcohol 571.6 Biliary cirrhosis 573.3 Hepatitis, unspecified 571.42 Autoimmune hepatitis

Table 3. Outcomes of Interest

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 16 of 33

Outcome of interest	Operationalization: ICD-10- CM code	Operationalization: ICD-9-CM code
	K72.90 Hepatic failure, unspecified without comaK72.91 Hepatic failure, unspecified with comaK73.0 Chronic hepatitisK73.0 Chronic persistent hepatitis, not elsewhere classifiedK73.1 Chronic lobular hepatitis, not elsewhere classifiedK73.2 Chronic active hepatitis, 	571.8 Other chronic nonalcoholic liver disease 573 Other disorders of the liver 573.0 Chronic passive congestion of liver 573.8 Other specified disorders of liver 570 Acute and subacute necrosis of liver 573.4 Hepatic infarction 572.3 Portal hypertension 572.4 Hepatorenal syndrome 573.5 Hepatopulmonary syndrome 571.8 Other chronic nonalcoholic liver disease 571.9 Unspecified chronic liver disease without mention of alcohol 573.9 Unspecified disorder of liver 782.4 Jaundice, unspecified, not of newborn

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 17 of 33

Outcome of interest	Operationalization: ICD-10- CM code	Operationalization: ICD-9-CM code
Interest	CM codeK75.2 Nonspecific reactive hepatitisK75.3 Granulomatous hepatitis, not elsewhere classifiedK75.4 Autoimmune hepatitisK75.4 Autoimmune hepatitisK75.81 Nonalcoholic steatohepatitis (NASH)K75.89 Other specified inflammatory liver diseasesK75.9 Inflammatory liver disease, unspecifiedK76.0 Fatty (change of) liver, 	
	K71.6 Toxic liver disease with hepatitis, not elsewhere classified	

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 18 of 33

Outcome of interest	Operationalization: ICD-10- CM code	Operationalization: ICD-9-CM code
	K71.2 Toxic liver disease with acute hepatitis K71.3 Toxic liver disease with chronic persistent hepatitis K71.4 Toxic liver disease with chronic lobular hepatitis K71.50 Toxic liver disease with chronic active hepatitis without ascites K71.51 Toxic liver disease with chronic active hepatitis with ascites R17 Unspecified jaundice	
Urticaria	L50.0 Allergic urticaria L50.1 Idiopathic urticaria L50.8 Other urticaria L50.9 Urticaria, unspecified	708.0 Allergic urticaria 708.1 Idiopathic urticaria 708.8 Other specified urticaria 708.9 Urticaria, unspecified
Angioedema	T78.3XXA Angioneurotic edema initial encounter T78.3XXD Angioneurotic edema subsequent encounter T78.3XXS Angioneurotic edema sequela	995.1 Angioneurotic edema, not elsewhere classified
Stevens- Johnson syndrome	L51.1 Stevens-Johnson syndrome L51.3 Stevens-Johnson syndrome -toxic epidermal necrolysis overlap syndrome	695.13 Stevens-Johnson syndrome 695.14 Stevens-Johnson syndrome- toxic epidermal necrolysis overlap syndrome
Lyell syndrome	L51.2 Toxic epidermal necrolysis [Lyell]	695.15 Toxic epidermal necrolysis

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 19 of 33

Outcome of interest	Operationalization: ICD-10- CM code	Operationalization: ICD-9-CM code
Erythema multiforme	L51.0 Nonbullous erythema multiforme L51.8 Other erythema multiforme L51.9 Erythema multiforme, unspecified	695.10 Erythema multiforme, unspecified 695.11 Erythema multiforme minor 695.12 Erythema multiforme major 695.19 Other erythema multiforme
Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)	D72.12 Drug rash with eosinophilia and systemic symptoms syndrome	
Interstitial nephritis Interstitial nephritis, also known as tubulointerstitial nephritis, is inflammation of the area of the kidney	N14.1 Nephropathy induced by other drugs, medicaments and biological substances N14.2 Nephropathy induced by unspecified drug, medicament or biological substance N14.4 Toxic nephropathy, not elsewhere classified N15.8 Other specified renal tubulo-interstitial diseases N15.9 Renal tubulo-interstitial disease, unspecified	583x Nephritis and nephropathy not specified as acute or chronic
Photosensitivity	L56.0 Drug phototoxic response L56.1 Drug photoallergic response L56.2 Photocontact dermatitis [berloque dermatitis] L56.4 Polymorphous light eruption L56.8 Other specified acute skin changes due to ultraviolet radiation	692.72 Acute dermatitis due to solar radiation 692.79 Other dermatitis due to solar radiation

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 20 of 33

Outcome of interest	Operationalization: ICD-10- CM code	Operationalization: ICD-9-CM code
Peripheral edema	R60.0 Localized edema R60.9 Edema, unspecified	782.3 Edema
Injection site thrombophlebitis	180.8 Phlebitis and thrombophlebitis of other sites 180.9 Phlebitis and thrombophlebitis of unspecified site T80.1 Vascular complications following infusion, transfusion and therapeutic injection T80.81 Extravasation of vesicant agent T80.90 Unspecified complication following infusion and therapeutic injection	451.89 Phlebitis and thrombophlebitis of other sites 451.9 Phlebitis and thrombophlebitis of unspecified site 999.2 Other vascular complications of medical care, NEC 909.3 Late effect of complications of surgical and medical care 999.82 Extravasation of another vesicant agent V58.89 Other specified aftercare 999.88 Other infusion reaction

Table 3.	Outcomes	of Interest
Table 5.	Outcomes	of interest

5.3. OTHER ENDPOINTS

The frequency of the 25 most common diagnostic codes (ICD-9-CM/ICD-10-CM) occurring within 30 days prior to starting or on the date of start of IV pantoprazole (ie, index date) through within 90 days of last treatment with IV pantoprazole among infants aged 1 month to <1 year and patients aged 1 to <2 years with a diagnosis of GERD (regardless of EE diagnosis).

5.4. KEY VARIABLES OF INTEREST

5.4.1. Demographic characteristics

Age on the index date will be calculated by subtracting the birth week from the index date. Sex will be either male or female. Race/ethnicity will be categorized as follows: White, Black, Asian, Hispanic, Other. Sex and race will be reported as last recorded value on index date.

PFIZER CONFIDENTIAL CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 21 of 33

5.4.2. Comorbidities

The following comorbidities will be identified based on the presence of at least one International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)/International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code or NDC/HCPCS codes identified using all available data during the baseline period and are operationalized in the table below.

History or presence of upper gastrointestinal anatomic or motor disorders	Operationalization: ICD- 10-CM code	Operationalization: ICD-9- CM code
Esophageal strictures, webs, diverticula, or other gastroduodenal pathology seen on esophagogastroduodenosco py	K22.2 Esophageal obstruction K57 Diverticular disease of intestine K22.5 Diverticulum of esophagus, acquired K31.5 Obstruction of duodenum Q39.3 Congenital stenosis and stricture of esophagus Q39.4 Esophageal web	530.3 Stricture and stenosis of esophagus 537.3 Other obstruction of duodenum 530.6 Diverticulum of esophagus, acquired 562 Diverticula of intestine 750.3 Congenital tracheoesophageal fistula, esophageal atresia and stenosis
Gastrointestinal strictures of any kind	K56.69x Other intestinal obstruction K50 Crohn's Disease	555 Regional enteritis 560.9 Unspecified intestinal obstruction, Enterostenosis; of intestine or colon: obstruction, occlusion, stenosis, stricture.
Esophageal or gastric motor disorders (eg, scleroderma)	C15 Malignant neoplasm of esophagus Z85.01 Personal history of malignant neoplasm of esophagus K31.84 Gastroparesis K91.1 Postgastric surgery syndromes	 150 Malignant neoplasm of esophagus 530 Diseases of esophagus 787.1 Heartburn V10.03 Personal history of malignant neoplasm of esophagus 536.3 Gastroparesis

Table 4. Operationalization of Comorbidities

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 22 of 33

History or presence of upper gastrointestinal anatomic or motor disorders	<i>Operationalization: ICD- 10-CM code</i>	Operationalization: ICD-9- CM code
	K20 Esophagitis K21 Gastro-esophageal reflux disease K22 Other diseases of esophagus R12 Heartburn K30 Functional dyspepsia K23 Disorders of esophagus in diseases classified elsewhere Q39 Congenital malformations of esophagus	564.2 Postgastric surgery syndromes 750.3 Congenital tracheoesophageal fistula, esophageal atresia and stenosis 750.4 Other specified congenital anomalies of esophagus 536.8 Dyspepsia and other specified disorders of function of stomach
Barrett's esophagus	K22.7x Barrett's esophagus	530.85 Barrett's esophagus
Peptic ulcer disease, erosive gastritis and/or erosive duodenitis	K25 Gastric ulcer K26 Duodenal ulcer K27.x Peptic ulcer, site unspecified K28 Gastrojejunal ulcer	 531 Gastric ulcer 532 Duodenal ulcer 533 Peptic ulcer site unspecified 534 Gastrojejunal ulcer
Eosinophilic esophagitis by histology (eosinophils per high powered field)	K20.0 Eosinophilic esophagitis	530.13 Eosinophilic esophagitis
Gastrointestinal malabsorption	K90 Intestinal malabsorption	579 Intestinal malabsorption

Table 4. Operationalization of Comorbidities

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 23 of 33

History or presence of upper gastrointestinal anatomic or motor disorders	Operationalization: ICD- 10-CM code	Operationalization: ICD-9- CM code
<i>H. pylori infection within the past 6 months</i>	B96.81 Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere	041.86 Helicobacter pylori [H. pylori]
Cystic Fibrosis	E84 Cystic fibrosis E84.8 Cystic fibrosis with other manifestations	277.0x Cystic fibrosis
Diagnosed as having or has received treatment for esophageal, gastric, pyloric channel, or duodenal ulceration		
Proton pump inhibitors	Operationalization: NDC code	Operationalization: HCPCS code
Omeprazole (Prilosec)	70515062501	NA*
Esomeprazole (Nexium)	00186504054, 00186504005, 00186504031	NA
Lansoprazole (Prevacid)	64764054130, 64764054105, 64764054111, 64764054119	NA
Rabeprazole (AcipHex)	62856024330	NA

Table 4. Operationalization of Comorbidities

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 24 of 33

History or presence of upper gastrointestinal anatomic or motor disorders	<i>Operationalization: ICD- 10-CM code</i>	Operationalization: ICD-9- CM code
Pantoprazole (Protonix) HCPCS Source	00008092351, 00008092355, 00008092360	S0164 Injection, pantoprazole sodium, 40 mg
H2-blockers		
Famotidine (Pepcid AC, Pepcid Oral) HCPCS Source	16837087210, 16837087220, 16837087222, 16837087230, 16837087231, 16837087260, 16837087275, 16837087290	J3490 Unclassified drugs
Cimetidine (Tagamet, Tagamet HB)	63029022201, 63029022202, 63029022203, 63029022204, 63029022205, 63029022270	NA
Ranitidine (Zantac, Zantac 75, Zantac Efferdose, Zantac injection, and Zantac Syrup) HCPCS Source	52565-102, 67751015101(for 150, max strength), 00173036238	J2780 Injection, ranitidine hydrochloride, 25 mg
Nizatidine Capsules (Axid AR, Axid Capsules, Nizatidine Capsules)	65726-144-15, 65726-145- 10	NA

Table 4. Operationalization of Comorbidities

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 25 of 33

Table 4.	Operationalization	of Comorbidities
	operationalization	of comorbiances

History or presence of upper gastrointestinal anatomic or motor disorders	<i>Operationalization: ICD- 10-CM code</i>	<i>Operationalization: ICD-9- CM code</i>
--	--	---

*NA = not available

5.4.3. Duration and dose of IV Pantoprazole

Duration of IV pantoprazole in days will be ascertained as follows: Date of last infusion during the observation period – date of first infusion during the observation period plus 1 day (minus treatment gaps, defined as a date with no record of infusion between the date of last infusion and date of first infusion; up to 7 days treatment gap between infusions will be allowed). Total daily dose of IV pantoprazole will be reported in mg/kg/day.

6. HANDLING OF MISSING VALUES

Patient events are excluded if patient identification (ID) attributed by Aetion is missing and if the "start of enrollment" date is preceded by the "end of enrollment" date in the original data. Additionally, patient events are excluded if there are no dates associated with them, or if the start date of the event is preceded by the end date of the event (e.g. discharge date precedes admission date for an inpatient event).

No imputation for missing values will be performed.

7. STATISTICAL METHODOLOGY AND STATISTICAL ANALYSES

7.1. STATISTICAL METHODS

All statistical analyses will be performed in the two cohorts of interest, ie, infants aged 1 month to < 1 year and patients aged 1 to < 2 years, separately using the Aetion's platform³, AEP version 4.2. Analyses combining the two cohorts of interest will not be performed.

Descriptive statistics will be presented for key variables of interest i.e., demographic characteristics, comorbidities, and duration and dose of IV pantoprazole to characterize the overall cohort treated with IV pantoprazole and in the 3 subgroups defined based on the presence or absence of GERD and EE as shown in table shells 1a-1d. Mean, median, minimum and maximum values, interquartile range (IQR), and standard deviation will be

PFIZER CONFIDENTIAL CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 26 of 33 provided for continuous variables when performing descriptive analysis of continuous data. Numbers and percentages will be provided for dichotomous and polychotomous variables when performing descriptive analysis of categorical data.

For analyses of estimation of incidence rates of the outcomes of interest during follow-up, each analysis will be restricted to patients without a history of outcome of interest prior to the index date (ie baseline period); thus, for each analysis of a given specified outcome, a distinct sub-cohort will be used (i.e. for the estimation of the incidence of hepatitis, only patients with prevalent cases of hepatitis in the baseline period will be excluded from followup and will not contribute to person-time at risk).

For each outcome of interest, patients will be followed from the index date to whichever of the following occurs first (follow-up period):

- Occurrence of an outcome of interest
- 90 days following the discontinuation of the first IV pantoprazole infusion (a gap of <7 days between administrations will be considered one episode)
- Initiation of a separate IV pantoprazole infusion within 90 days following discontinuation of IV pantoprazole administration, where a separate infusion is defined as the subsequent administration at least 7 days from the end of the previous infusion
- Death
- End of enrollment in the database
- End of study period (ie, December 31, 2020).

Incidence rates of each prespecified outcome of interest will be estimated as the number of patients with a specific outcome of interest during the follow-up period divided by the total person-time at risk and reported as incidence per 1,000 person-years with associated 95% CIs, assuming a Poisson distribution. Exact Poisson confidence limits for the estimated rate are found as the Poisson means, for distributions with the observed number of events and probabilities relevant to the chosen confidence level, divided by time at risk.

$$egin{aligned} Y_l &= rac{\chi^2_{2Y,\;lpha/2}}{2} \ Y_u &= rac{\chi^2_{2(Y+1),\;1-lpha/2}}{2} \end{aligned}$$

- where Y is the observed number of events, Yl and Yu are lower and upper confidence limits for Y respectively, $\chi 2v$, a is the chi-square quantile for upper tail probability on v degrees of freedom.

For the analysis of the primary objective, incidence rates for all outcomes of interest will be estimated in the overall cohort and in subgroups 1 and 2. These results will be displayed as shown in table shells 2a-2c. Within the overall cohort and in the subgroups, incidence rates will be calculated by duration of IV pantoprazole treatment (<4 days, \geq 4 days) as shown in table shells 3a-3c. For the analysis of the secondary objective 1, incidence rates will be

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 27 of 33

090177e19a9b0eb9\Approved\Approved On: 30-Jun-2022 03:30 (GMT)

estimated for the overall population in each cohort (table shell 2d) and by duration of IV pantoprazole treatment (<4 days, \geq 4 days) within each cohort (table shell 3d). For the analysis of the secondary objective 2, counts of the 25 most common diagnostic codes occurring within 30 days prior to starting or on the date of start of IV pantoprazole (ie, index date) and within 90 days of last treatment with IV pantoprazole in the subsets of patients with a diagnosis of GERD regardless of EE status (ie, subgroups 1 and 2 combined) will be generated. These results will be displayed in table shell 4a for cohort 1 and 4b for cohort 2). For each patient, reoccurring codes within 30 days prior to starting or on the date of start of IV pantoprazole (ie, index date) and within 90 days of last treatment with IV pantoprazole will be counted once.

7.2. STATISTICAL ANALYSES

See Section 7.2.3

7.2.1. Safety Analyses

N/A

7.2.2. Sensitivity Analyses

The following sensitivity analyses will be conducted. The results from the first sensitivity analysis will be displayed in table shell 5a and results from the second sensitivity analysis will be displayed as shown in table shell 5b.

Table 5.Sensitivity Analyses

Sensitivity Analysis	Description	Rationale
Sensitivity to enforced 30- day enrollment period prior to the index date	Perform analysis in both cohorts without exclusion criteria of at least 30-day enrollment prior to the index date.	Given the age of the study population, patients may not be enrolled in the database for greater than 30 days prior to the index date and it will be important to include such patients in the analysis and examine the incidence rates of outcomes of interest.
Sensitivity to ICD-9-CM versus ICD-10-CM coding	Perform analysis in both cohorts, stratified by those patients identified via	ICD-9-CM coding for subgroup identification is less specific than ICD-10-CM based on

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 28 of 33

Sensitivity Analysis	Description	Rationale
for subgroup classification.	ICD-9-CM codes versus ICD-10-CM codes, respectively.	Lopushinsky et al. 2007 ² . Stratifying incidence rates and comparing incidence estimates between strata will allow us to understand comparability between patient cohorts identified using different coding schemes and any potential heterogeneity in patients and incidence rates of outcomes of interest.

Table 5.Sensitivity Analyses

7.2.3. Summary of Analyses

Table 6.	Summary	of Analyses
----------	---------	-------------

Outcome	Analy sis Set	Supports Protocol Objective Number	Subgroup	Statistica l method	Table Shell Number	Covariates/ Strata	Missing Data
Each of 27 outcomes of interest described in <u>Section</u> <u>5.2</u>	FAS	Primary Objective 1	Subgroup s 1 and 2	Descripti ve Statistics ; Incidenc e Rate per 1,000 Person- Years	Table 1a-1c; Tables 2a-2c, 3a-3c	N/A	Excluded
Each of 27 outcomes of interest described in <u>Section</u> <u>5.2</u>	FAS	Secondary Objective 1	Subgroup 3	Descripti ve Statistics ; Incidenc e Rate per 1,000	Table 1d; Tables 2d, 3d	N/A	Excluded

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 29 of 33

Outcome	Analy sis Set	Supports Protocol Objective Number	Subgroup	Statistica l method	Table Shell Number	Covariates/ Strata	Missing Data
				Person- Years			
Most Common ICD codes	FAS	Secondary Objective 2	Subgroup s 1 and 2	Descripti ve Statistics	Tables 4a-4b	N/A	Excluded
Each of 27 outcomes of interest described in <u>Section</u> <u>5.2</u>	FAS	Sensitivity Analysis 1	None	Incidenc e Rate per 1,000 Person- Years	Table 5a	N/A	Excluded
Each of 27 outcomes of interest described in <u>Section</u> <u>5.2</u>	FAS	Sensitivity Analysis 2	None	Incidenc e Rate per 1,000 Person- Years	Table 5b	N/A	Excluded

Table 6.Summary of Analyses

090177e19a9b0eb9\Approved\Approved On: 30-Jun-2022 03:30 (GMT)

8. LIST OF TABLES AND TABLE SHELLS

Table 1a	Baseline Characteristics of Main Study Cohorts
Table 1b	Baseline Characteristics of Subgroup 1: GERD with EE
Table 1c	Baseline Characteristics of Subgroup 2: GERD without EE
Table 1d	Baseline Characteristics of Subgroup 3: No Dx of GERD/EE
Table 2a	Incidence of Outcomes of Interest During the Follow-Up Period Among Main Study Cohorts
Table 2b	Incidence of Outcomes of Interest During the Follow-Up Period Among Subgroup 1: GERD with EE
Table 2c	Incidence of Outcomes of Interest During the Follow-Up Period Among Subgroup 2: GERD without EE
Table 2d	Incidence of Outcomes of Interest During the Follow-Up Period Among Subgroup 3: No Dx of GERD/EE
Table 3a	Incidence of Outcomes of Interest During the Follow-Up Period Among the Study Cohorts Stratified By Duration of pantoprazole Treatment
Table 3b	Incidence of Outcomes of Interest During the Follow-Up period Among Subgroup 1: GERD with EE Stratified By Duration of pantoprazole Treatment
Table 3c	Incidence of Outcomes of Interest During the Follow-Up Period Among Subgroup 2:

Table 7.List of Table Shells

PFIZER CONFIDENTIAL

CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 31 of 33

	GERD without EE Stratified By Duration of pantoprazole Treatment
Table 3d	Incidence of Outcomes of Interest During the Follow-Up Period Among Subgroup 3: No Dx of GERD/EE Stratified By Duration of pantoprazole Treatment
Table 4a	Top 25 Diagnostic Codes Among Cohort 1: Infants Aged 1 Month - <1 Year
Table 4b	Top 25 Diagnostic Codes Among Cohort 2: Infants Aged 1 Year - <2 Years
Table 5a (Sensitivity Analysis 1)	Incidence of Outcomes of Interest During the Follow-Up Period Among Main Study Cohorts, Sensitivity Analysis 1: No Requirement for Minimum 30 Day Baseline Period
Table 5b (Sensitivity Analysis 2)	Incidence of Outcomes of Interest During Follow-Up Period Among Main Study Cohorts, Sensitivity Analysis 2: ICD9 vs ICD10 Coding

Table 7.List of Table Shells

9. REFERENCES

- 1. Optum® de-identified Electronic Health Record dataset (2007-2019)
- 2. Lopushinsky, S.R., Covarrubia, K.A., Rabeneck, L. et al. Accuracy of administrative health data for the diagnosis of upper gastrointestinal diseases. Surg Endosc 21, 1733–1737 (2007).
- 3. Action Evidence Platform. Action. Accessed January 12, 2022. https://action.com/platform/

PFIZER CONFIDENTIAL CT24-WI-GL03-RF03 2.0 Non-Interventional Statistical Analysis Plan For Secondary Data Collection Study 01-Jun-2020 Page 32 of 33

10. APPENDICES

10.1. APPENDIX 1: DATA DERIVATION DETAILS

The data were subject to quality control procedures. The data provider was contacted to help rectify any problems identified during the quality control procedures, including if the files received appeared to be incomplete or the data values were implausible. The data are loaded into the Aetion Evidence Platform after minimal processing into patient longitudinal timelines to enable representation of the original data and without any data loss. Events are required to have a valid start date. Record counts are cross-checked for validation and compared to the original data counts.

10.1.1. Definition and use of visit windows in reporting

N/A

10.1.2. Further definition of endpoints

10.2. APPENDIX 2: ADDITIONAL STATISTICAL METHODOLOGY DETAILS

N/A

10.2.1. Further Details of the Statistical Methods

10.3. APPENDIX 3: DIAGNOSIS AND PROCEDURE CODES USED IN THE STUDY

N/A